A short and readable commentary on monoclonal antibodies and dyslipidaemias, particularly on FOURIER, SPIRE and ODYSSEY trials
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Cardiac Guidelines
February 5, 2017
A review of particular interest for procurement (retrieval) of hearts after brain injury, especially subarachnoid bleeding, the commonest cause of death in DBD in our practice. The authors discuss, amongst other things, the early stress micro-infarcts that may limit the performance of the donated heart, especally in female donors with sub a
July 13, 2016
The authors enrolled 149 patients on DAPT undergoing urgent cardiac surgery in a prospective study analyzing the association between platelet reactivity and postoperative bleeding. They found that decreasing platelet reactivity correlated with an increase in calculated red blood cell loss after surgery.
April 21, 2016
These authors analyzed retrospectively the effect of postoperative fibrinogen level on bleeding after heart surgery in their database of 2,800 patients. They found that serum fibrinogen levels lower than 220 mg/dl more than doubled the risk of postoperative bleeding.
April 3, 2016
Neil Moat, one of the busiest British surgeons involved directly and consistently in TAVR, discusses PARTNER 2 and SURTAVI, paying particular attention to the health economics of low-risk TAVR and the implication of reduced profile devices.
March 31, 2016
The fourth (re- )classification of cardiopericardial tumours came from the World Health Organisation last year, 11 years after the third. In particular, the malignant fibrous histiocytomas are re classified as undifferentiated pleomorphic sarcomas.
March 23, 2016
Guidelines recommend that ICDs should not be implanted until after 90 days following revascularization in patients with an EF<35% and an MI. Studies have shown that no clinical benefit or detriment was derived by implantation prior to 90 days.
March 11, 2016
The authors provide an excellent overview of the rationale for screening all patients with a new diagnosis of cardiomyopathy for coronary artery disease. This rationale includes the following:
December 16, 2015
PREVENT IV trial participants who had undergone either a RIMA or LIMA to LAD anastomosis and underwent an angiogram at 1 to 1.5 years (n=1539) were analyzed for mammary graft failure (defined as >75% stenosis).
December 10, 2015
A growing body of evidence demonstrates improved short, mid, and long term outcomes with the use of arterial conduits for coronary revascularization. Despite this, less than 10% of patients receive more than 2 arterial grafts.